MétaCan
Menu
← Back to cohort
Record W2912300456 · doi:10.1093/ecco-jcc/jjy222.515

P391 Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?

2019· article· en· W2912300456 on OpenAlexaboutno aff
Teresa Valdés Delgado, M Guerra Veloz, María Belvis Jiménez, Belén Maldonado Pérez, Luisa Castro Laria, A. Benítez Roldán, Raúl Perea Amarillo, Vicente Merino Bohórquez, Miguel Ángel Calleja Hernández, Tamara Ortíz, Ángel Caunedo Álvarez, Ángel Vilches‐Arenas, Antonia Sáez Díaz, Federico Argüelles‐Arias

Bibliographic record

VenueJournal of Crohn s and Colitis · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineInfliximabInternal medicineDosingCrohn's diseaseGastroenterologyInflammatory bowel diseaseRetrospective cohort studyUlcerative colitisObservational studyDisease

Abstract

fetched live from OpenAlex

It has been seen that 30–40% of patients treated with Infliximab (IFX) who achieve an initial response to induction therapy lose this response over time with maintenance treatment. Therapeutic drug monitoring (TDM) could be used to optimise management in such situations. However, IFX serum levels are not well defined. The aim of the study was to find our cut-off range of Infliximab serum levels in Crohn’s disease (CD) patients in remission in clinical practice. An observational retrospective study was developed from 1 February 2016, to 30 November 2017, in our hospital. Patients with established CD who had been on maintenance dosing schedule of IFX were included. IFX and antibody to IFX levels were measured before each infusion at least twice and after 6 months of treatment in all patients. All the tests were performed using enzyme linked immunosorbent assay (ELISA) with Progenika kits (PROMONITOR®). Clinical remission was defined using Harvey–Bradshaw Index (HBI ≤ 4). The interpretation of data was by cluster analysis (Silhouette measure of cohesion and separation: cluster quality >0.51). 105 CD patients were included in the study, 57.1% men, with a mean age of 39 (DE ± 12.9). The median (range) time of the disease was 11 years (7–15). The median (range) time of follow-up was 32 months (22–38). Montreal phenotypes were: 76% A2, 35.2% L2 and 53.3% B1. Perianal disease was present in 51.4%. 265 IFX levels were measured during the follow-up. Patients who achieved remission had IFX serum levels between 4.26 and 8.26 μg/ml vs. 0.06 and 1.43 μg/ml in patients who did not achieve remission (silhouette 0.72) the first time; and 2.84–7.75 μg/ml vs. 0.05–2.69 μg/ml in patients who achieved remission vs. those who did not achieve remission, respectively the second time (silhouette 0.78) (Figure 1). Cluster IFX-levels both times. 4.26–7.75 μg/ml were the best cut-off range for remission (Table 1). IFX-levels range in both times. We found that perianal disease does not have any influence on IFX serum levels for achieved remission. In our practice, the best value to predict remission status in patients undergoing IFX TDM was found to be 4–8 μg/ml, which was higher than in other studies. Reference 1. Kaufman L, Rousseeuw PJ. Finding Groups in Data. An Introduction to Cluster Analysis. New York: John Wiley & Sons; 1990. doi:10.1002/9780470316801.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.027
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.044

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.027
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.003
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.301
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→